Edition:
India

Acer Therapeutics Inc (ACER.OQ)

ACER.OQ on NASDAQ Stock Exchange Capital Market

2.18USD
19 Aug 2019
Change (% chg)

-- (--)
Prev Close
$2.18
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
65,675
52-wk High
$34.10
52-wk Low
$1.88

About

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The... (more)

Overall

Beta: 1.44
Market Cap(Mil.): $27.24
Shares Outstanding(Mil.): 10.09
Dividend: --
Yield (%): --

Financials

FDA declines to approve Acer Therapeutics' rare genetic disorder treatment

Acer Therapeutics Inc said on Tuesday the U.S. Food and Drug Administration declined to approve its treatment for a severe, rare genetic disorder that can cause blood vessels to fatally rupture, sending its shares plunging as much as 78%.

25 Jun 2019

UPDATE 2-FDA declines to approve Acer Therapeutics' rare genetic disorder treatment

June 25Acer Therapeutics Inc said on Tuesday the U.S. Food and Drug Administration declined to approve its treatment for a severe, rare genetic disorder that can cause blood vessels to fatally rupture, sending its shares plunging as much as 78%.

25 Jun 2019

FDA declines to approve Acer Therapeutics' treatment for rare genetic disorder

Acer Therapeutics Inc said on Tuesday its treatment for a severe, rare genetic disorder that can cause blood vessels to fatally rupture was declined approval from the U.S. Food and Drug Administration.

25 Jun 2019

FDA declines to approve Acer Therapeutics' treatment for rare genetic disorder

June 25Acer Therapeutics Inc said on Tuesday its treatment for a severe, rare genetic disorder that can cause blood vessels to fatally rupture was declined approval from the U.S. Food and Drug Administration.

25 Jun 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates